Skip to content
value.today

Cingulate Therapeutics

🇺🇸 Morristown, New Jersey, USAPharmaceuticalsFounded 2012
Total raised
$26 M
1 round on record
Latest round
$26 M
Nov 2013
First round on record
Nov 2013
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cingulate Therapeutics
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2013$26 MNo. 1$10 to $50 million

Cingulate Therapeutics: Raise no. 1, Nov 2013

Investors in this round

203 investors had bought by the notice of Jun 29, 2020: 203 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M (amount offered: indefinite)
Smallest investment taken
$100,000
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Membership Units, Profits Interest Units
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,250,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Craig Steven Gilgallon · Executive Officer
  • Laurie A Myers · Executive Officer
  • Louis George Van Horn · Executive Officer
  • Matthew N Brams · Executive Officer, Director
  • Raul R Silva · Executive Officer
  • Shane J Schaffer · Executive Officer, Director
  • Arthur B Straughn · Director
  • Jeff J Conroy · Director
  • Jeff J Hargroves · Director
  • Patrick J Gallagher · Director
  • Peter J Werth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Annual executive payroll estimate.”

Signed by Louis G. Van Horn, Chief Financial Officer. Source: SEC Form D and 4 amendments, newest notice filed Jun 29, 2020. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cingulate Therapeutics had no revenue when it filed its newest notice of a funding round (Jun 2020).

    SEC Form D (revenue range) · Jun 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cingulate Therapeutics is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 203 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cingulate Therapeutics
NameRoleNamed in
Craig Steven GilgallonExecutive officerJun 2020
Laurie A MyersExecutive officerJun 2020
Louis George Van HornExecutive officerJun 2020
Matthew N BramsExecutive officerJun 2020
Raul R SilvaExecutive officerJun 2020
Shane J SchafferExecutive officerJun 2020
Shane j SchafferExecutive officerJul 2018
Craig Stephen TashjyExecutive officerMay 2017
Arthur B StraughnDirectorJun 2020
Jeff J ConroyDirectorJun 2020
Jeff J HargrovesDirectorJun 2020
Matthew N BramsDirectorJun 2020
Patrick J GallagherDirectorJun 2020
Peter J WerthDirectorJun 2020
Shane J SchafferDirectorJun 2020
Shane j SchafferDirectorJul 2018
Laurie A MyersDirectorJan 2018